These findings underscore the potential significance of high NKAIN1 protein expression in gastric cancer tissues during clinical diagnosis and treatment, suggesting that immune checkpoint inhibitors targeting CTLA-4 or PD-1/PD-L1 could be considered to improve therapeutic outcomes. The gene discussed is NKAIN1; the disease is gastric cancer.